SV

Street Verdict

Analyst Scorecard

DRREDDY · NSE

Dr. Reddy's Laboratories Limited

₹1,390.2

-0.76% (-₹10.7)

Prev. close

₹1,400.9

Volume

8,30,660

Delivery %

49.2%

As of

20 Nov 2026

Price history

₹1,390.2+₹211.4 (+17.93%) · 3M
18 Aug 2026 → 20 Nov 2026
1,1501,2001,2501,3001,3501,40018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

Analysts lean bullish

3 analyst stances · last 90 days · one per analyst

Trackable

3 · 3 bull / 0 neutral / 0 bear

Long-Horizon

none in range

Commentary

none in range

Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded

Bullish 100% (3)Neutral 0% (0)Bearish 0% (0)
Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions
Market commentary · 15 · levels, conditionals, previews, macro & hedged views — context, not graded
CallAnalystInstrumentVerdictActions

Fundamentals

About Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Details

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Mr. Erez Israeli M.B.A.

Headquarters

Hyderabad

Employees

27,527

Key stats

Market cap

₹1.14 L Cr

P/E ratio (TTM)

40.6

Dividend yield

0.58%

EPS (TTM)

₹33.59

Beta (1Y · daily vs NIFTY 50)

0.47

Beta (5Y · monthly vs NIFTY 50)

0.41

Shares float

60.01 Cr

EPS · quarter ended Sept 2026

₹11.10

Upcoming earnings

21 Jan 2027

Financial Performance

01 · Financials

0 Cr10000 Cr20000 Cr30000 Cr40000 Cr₹0%5%10%15%20%FY21FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

0255075₹FY21FY22FY23FY24FY25FY26

03 · Dividend Profile

02468₹0%10%20%30%40%13 Jul 2009 Jul 2111 Jul 2211 Jul 2316 Jul 2410 Jul 2510 Jul 26
Dividend (₹/share)Annualised yieldAnnual dividend growth (FY)

Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-50%0%50%100%FY21FY22FY23FY24FY25FY26
SalesFixed assetsReceivables (trade + unbilled)Inventory

05 · Capital Structure & Asset Utilization

0 Cr20000 Cr40000 Cr60000 Cr₹0×0.2×0.4×0.6×0.8×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr20000 Cr40000 Cr60000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

0 Cr2000 Cr4000 Cr6000 Cr8000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹19,047.50 Cr₹21,545.20 Cr₹24,669.70 Cr₹28,011.10 Cr₹32,643.90 Cr₹33,700.20 Cr
EBITDA
₹4,161.30 Cr₹4,252.10 Cr₹7,443.10 Cr₹8,827.40 Cr₹9,644.40 Cr₹7,916.00 Cr
₹1,952.00 Cr₹2,182.00 Cr₹4,506.70 Cr₹5,577.90 Cr₹5,655.10 Cr₹4,285.00 Cr
Diluted EPS
₹23.47₹26.24₹54.18₹66.92₹67.79₹51.42

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹26,616.80 Cr₹29,746.90 Cr₹32,285.10 Cr₹38,780.00 Cr₹48,023.00 Cr₹56,577.00 Cr
₹3,030.80 Cr₹3,004.50 Cr₹608.20 Cr₹2,002.00 Cr₹4,676.60 Cr₹7,734.10 Cr
Stockholders' equity
₹17,641.70 Cr₹19,212.40 Cr₹23,286.10 Cr₹28,254.00 Cr₹33,549.00 Cr₹37,892.00 Cr

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹3,570.30 Cr₹2,810.80 Cr₹5,888.00 Cr₹4,543.00 Cr₹4,643.00 Cr₹5,674.00 Cr
Investing cash flow
₹-2,266.00 Cr₹-2,638.70 Cr₹-4,137.10 Cr₹-4,028.30 Cr₹-5,807.70 Cr₹-6,549.30 Cr
₹-29.80 Cr₹-242.20 Cr₹-2,686.10 Cr₹-376.30 Cr₹1,891.10 Cr₹829.00 Cr
Capital expenditure
₹-1,256.10 Cr₹-1,904.90 Cr₹-1,887.00 Cr₹-2,744.00 Cr₹-3,440.00 Cr₹-3,840.00 Cr
End cash position
₹1,482.90 Cr₹1,485.20 Cr₹577.90 Cr₹710.70 Cr₹1,459.30 Cr₹1,536.80 Cr

Debt issued, Debt repaid have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21Dec 21–Mar 22(2Q)Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24–Dec 24(2Q)Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Promoter26.72%26.72%26.71%26.71%26.70%26.70%26.69%26.66%26.65%26.65%26.65%26.64%26.64%26.64%26.64%26.64%26.63%26.64%
Public72.99%73.00%73.01%73.02%73.05%73.08%73.10%73.16%73.17%73.17%73.18%73.20%73.07%73.10%73.11%73.12%73.13%73.16%
Employee trusts0.29%0.28%0.28%0.27%0.25%0.22%0.21%0.18%0.18%0.17%0.17%0.16%0.29%0.26%0.25%0.25%0.24%0.20%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Lupin Limited₹92,244.53 Cr₹2,008.616.74.1123.8%0.29+23.9%+0.6%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

DRREDDY

Dr. Reddy's Laboratories rallies Monday, outperforms competitors

MarketWatch · 6 days ago

DRREDDY

Pharma sector stocks today, November 9: Aarti Drugs jumps 6.96%, Divi's Laboratories up 5.73%, Mankind Pharma rises 3.69%

Business Upturn · 13 days ago